



## Drug Utilization Review Board Meeting

<u>Date</u>	<u>Time</u>	<u>Location</u>
January 18, 2023	10:00am – 3:00pm (CST)	MHD Building 615 Howerton Ct, Jefferson City, MO 65101 OR WebEx

[\\* Click HERE for Meeting Documents \\*](#)

### **Board Members Present**

Charlene Heyde, PharmD  
Ginger Nicol, MD, CEDS  
Jennifer Passanise, FNP-BC  
Julie Ferguson, DO  
Kimberly Eisenstein, MD  
Lisa Pierce, MD  
Rick Kegler, PharmD  
Sandra Bollinger, PharmD  
Susan Abdel-Rahman, PharmD, Chair

### **Board Members Absent**

Stacy Mangum, PharmD

### **MO HealthNet Staff Present**

Angela Wilson, Pharmacy Operations Manager  
Carmen Burton, Pharmacy Support Assistant  
Connie Sutter, Fiscal Manager  
Desiree Vitale, Special Counsel  
Elizabeth Short, Program Development Specialist  
Elizabeth Sissom, RN, Clinical Review Nurse  
Jamie Herzing, Benefit Program Senior Specialist  
Joshua Moore, PharmD, Director of Pharmacy  
Lisa Smith, Pharmacy RFP Coordinator  
Mark Roaseau, R.Ph, Clinical Pharmacist  
Nikki Ashley, Pharmacy Program Specialist  
Timothy Kling, MD, Acting Medical Director

### **Contractors Present**

Amanda Williams, PharmD, RPh, Gainwell Technologies  
Amy Culley, PharmD, Conduent  
Ashley Lytton, RN, BSN, Wipro  
Chelsea Pendleton, RN, BSN, Wipro  
Dimple Patel, PharmD, Conduent  
Jennifer Colozza, PharmD, Conduent  
John Crowley, PharmD, BCPS, CPPS, Conduent  
Karen Powell, PharmD, MS, Gainwell Technologies  
Lokendra Upadhyay, PharmD, Conduent  
Lynn Morsches, PharmD, Conduent  
Mandy Nilges, RN, Wipro  
Megan Fast, PharmD, Gainwell Technologies  
Paul Fung, PharmD, MHA Conduent  
Sandy Kapur, PharmD, Gainwell Technologies  
Serena Barden, PharmD, BCPS, Gainwell Technologies  
Vicki Revel, PharmD, Gainwell Technologies

**Others Present:**

Amanda Nowakowski

Atria Solutions

Beth Kingeter

Brian Strickland

Camille Kerr

Cheryl Marten

Dave Miley

David Large

Donald Nopper

Eric Hyde

Erin Hohman

Fabi Garcia

Gary Parenteau

Gene McCarty

Jamie Tobitt

Jeff Knappen

Jen Tamburo

Jennifer Rattan

Jenny Phone

Jessica Petrie

John Bullard

Jomy Joseph

Jordon Wild

Keith Gulley

Keith Rose

Kurt Hendrickson

Kyle W

Lee Ward

Melissa Basil

Michele Shirley

Nancy N.

Paul Saskin

Phil Lohec

Richie Craul

Ricki Roberson

Robert Pearce

Roberto Pedraza

Sara Hovland

Sean

Shauna Williams

Shelly Nickerson

Tami Sova

Teresa Blair

<p><b>Welcome, Announcements and Introductions</b></p>	<p>Susan Abdel-Rahman, Board Chair, called the meeting to order.</p> <p>Joshua Moore, MHD Director of Pharmacy, introduced himself along with Nikki Ashley. Joshua facilitated the meeting on behalf of the MO HealthNet Division.</p>
<p><b>Minutes Review</b></p>	<p><b>Discussion:</b> Minutes were reviewed from the October meeting.</p> <p><b>Decision:</b> The Board voted to accept these approved minutes with no revisions.</p>
<p><b>Pharmacy Program and Budget Update</b></p>	<p>Elizabeth Short, Joshua Moore and Elizabeth Sissom presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> <li>- December 2022 Enrollees and Expenditures</li> <li>- July – December 2022 Expenditures by Service</li> <li>- FY20 – FY23 Pharmacy Expenditures vs Total Medicaid Expenditures</li> <li>- December 2022 Medicaid Expansion Participants, Expenditures, and Claim Count</li> <li>- December 2022 Top Ten Reimbursed Drugs</li> <li>- December 2022 Top Ten Reimbursed Drugs for Children 0-17</li> <li>- CY2022 PUPM Drug Claim Reimbursement</li> <li>- Additional updates were provided on: <ul style="list-style-type: none"> <li>○ Prior Authorization Process</li> <li>○ Clinical initiatives <ul style="list-style-type: none"> <li>▪ CGMs</li> <li>▪ Project Hep Cure</li> </ul> </li> <li>○ State Plan Amendment for Value Base Agreement <ul style="list-style-type: none"> <li>▪ Received CMS approval</li> </ul> </li> <li>○ Proposed Rule on med sync and auto refill <ul style="list-style-type: none"> <li>▪ Open for public comment</li> </ul> </li> <li>○ Maternal Infant Health Efforts</li> </ul> </li> </ul>

Old Business	
Old Business	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: <a href="https://dss.mo.gov/mhd/cs/advisory/dur/meeting.htm">https://dss.mo.gov/mhd/cs/advisory/dur/meeting.htm</a></p>
New Business	
New Drug Review	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> <li>o A listing of products recommended for open access, clinical edit, step therapy, preferred drug list (PDL), or continue prior authorization was emailed to the Board for discussion and action.</li> </ul> </li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the presented new drug recommendations with no revisions.</p>

Clinical and Fiscal Edit Review	
Clinical & Fiscal Edits With No Annual Changes	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> <li>o Aduhelm Clinical Edit</li> <li>o Antipsychotics, 1st Generation (Typical) Clinical Edit</li> <li>o Benzodiazepine, Select Oral Clinical Edit</li> <li>o Butalbital Combinations without Codeine Clinical Edit</li> <li>o Corlanor Clinical Edit</li> <li>o Empaveli Clinical Edit</li> <li>o HBV Nucleotide Analog Reverse Transcriptase Inhibitors Fiscal Edit</li> <li>o High Risk Therapies Clinical Edit</li> <li>o Kerendia Clinical Edit</li> <li>o Morphine Milligram Equivalent (MME) Accumulation Clinical Edit</li> <li>o Non-Oral Contraceptives Fiscal Edit</li> <li>o Oxazolidinone Fiscal Edit</li> <li>o Pompe Disease Clinical Edit</li> <li>o Selzentry Clinical Edit</li> <li>o Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit</li> <li>o Verquvo Clinical Edit</li> </ul> </li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
Camzyos Clinical Edit	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center"><b>Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center"><b>Opioids, Short Acting Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center"><b>Skysona Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center"><b>Xenpozyme Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center"><b>Ztalmy Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>

<p><b>Zynteglo Clinical Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<p><b>Resource List Edit Review</b></p>	
<p><b>Antipsychotics – 2<sup>nd</sup> Generation (Atypical) Depot Agents</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<p><b>Antipsychotics – 2<sup>nd</sup> Generation (Atypical) Oral and Transdermal Agents</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>

Preferred Drug List Edit Review	
<p><b>Preferred Drug Edits With No Annual Changes</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>○ Alzheimer's Agents, AChEIs and NMDA Receptor Antagonists &amp; Combinations PDL Edit</li> <li>○ Antiemetics, 5-HT3 and NK1 Injectables PDL Edit</li> <li>○ Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables PDL Edit</li> <li>○ Anti-Migraine, Serotonin (5-HT1) Receptor Agonists PDL Edit</li> <li>○ Anti-Parkinsonism, MAO-B Inhibitors PDL Edit</li> <li>○ Anti-Parkinsonism, Non-Ergot Dopamine Agonists PDL Edit</li> <li>○ Antiplatelet Agents PDL Edit</li> <li>○ Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors PDL Edit</li> <li>○ Glucagon Agents PDL Edit</li> <li>○ Hereditary Angioedema Agents PDL Edit</li> <li>○ NSAIDs PDL Edit</li> <li>○ Opioid Emergency Reversal Agents PDL Edit</li> <li>○ Opioids, Long Acting PDL Edit</li> <li>○ Somatostatin Analogs PDL Edit</li> <li>○ Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors PDL Edit</li> </ul> <ul style="list-style-type: none"> <li>- Public comment provided by: <ul style="list-style-type: none"> <li>○ David Miley with Teva was available for questions on Austedo</li> </ul> </li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<p><b>Antiandrogenic Agents PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>



<b>Anticonvulsants, Dravet Syndrome PDL Edit</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<b>Anti-Migraine, Alternative Oral Agents PDL Edit</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- Public comment provided by: <ul style="list-style-type: none"> <li>o Erin Hohman with Abbvie on Ubrelvy</li> </ul> </li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<b>Antiretroviral Therapy (ART) PDL Edit</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<b>Calcitonin Gene-Related Peptide (CGRP) Inhibitors PDL Edit</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- Public comment provided by: <ul style="list-style-type: none"> <li>o David Miley with Teva was available for questions on Ajovy</li> <li>o Jordon Wild with Amgen on Aimovig</li> </ul> </li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<b>Fibromyalgia Agents PDL Edit</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>

<p><b>GI Motility Agents, Chronic PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<p><b>Mitogen-activated Extracellular Kinase Inhibitors (MEKi) &amp; B-raf Kinase Inhibitors (BRAFi) PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<p><b>Neuropathic Pain PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<p><b>Opioid &amp; Select Alcohol Dependence Agents PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<p><b>Sedative Hypnotics PDL Edit</b></p>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- Sandra Bollinger proposed to change the trial period for Dayvigo and Quviviq from 30 days to 10 days</li> <li>- Public comment provided by: <ul style="list-style-type: none"> <li>o Paul Saskin with Idorsia Pharmaceuticals on Quviviq</li> </ul> </li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with the proposed change.</p>

<b>Skeletal Muscle Relaxants PDL Edit</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<b>Tramadol-Like Agents PDL Edit</b>	<p><b>Discussion:</b></p> <ul style="list-style-type: none"> <li>- Joshua Moore introduced the edit for discussion to the Board.</li> <li>- No other discussion.</li> <li>- No public comment provided.</li> </ul> <p><b>Decision:</b> The Board voted to accept the recommended criteria with no additional revisions.</p>
<b>Other Business</b>	
<b>Program Utilization Information – Conduent Update</b>	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> <li>- Top 25 Drugs by Paid Amount 1<sup>st</sup> Quarter SFY23 (July, August, September)</li> <li>- Top 25 Drugs by Paid Number 1<sup>st</sup> Quarter SFY23 (July, August September)</li> <li>- Helpdesk Status Report November 2022</li> <li>- POS Transaction Report</li> </ul>
<b>RetroDUR Update</b>	<p>Dimple Patel with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> <li>- Recent RetroDUR Interventions: <ul style="list-style-type: none"> <li>o Preventing Overdose in Patients Using Medication-Assisted Treatment (MAT)</li> </ul> </li> <li>- Outcome Assessment: <ul style="list-style-type: none"> <li>o Glucagon Intervention</li> </ul> </li> <li>- Potential RetroDUR Interventions: <ul style="list-style-type: none"> <li>o Continuous Glucose Monitors (GCM)</li> </ul> </li> <li>- Other RetroDUR Interventions: <ul style="list-style-type: none"> <li>o Long acting injectable (LAI) antipsychotic use in Schizophrenia</li> </ul> </li> </ul>
<b>Motion to Close</b>	<p>Lisa Pierce motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.</p>

<b>Executive Session</b>	MO HealthNet data analysis was reviewed with the Board during Executive Session.
--------------------------	--

**NEXT MEETING: Thursday, April 20, 2023**  
615 Howerton Court, Conference Room 202  
Jefferson City, MO 65109 and WebEx

Roll Call for January 18, 2022				
	<u>Action Item</u>			
<u>Board Member</u>	October Meeting Minutes	All Recommendations: Block Vote for CE, FE and PDL Edits	Closing	Adjournment
Susan Abdel-Rahman	Y	Y	Y	A
Charlene Heyde	Y	Y-S	Y	A
Sandra Bollinger	A	Y	Y	Y
Julie Ferguson	Y	Y	Y	Y
Lisa Pierce	Y-M	Y-M	Y-M	Y-M
Jennifer Passanise	Y	Y	Y	Y
Stacy Mangum	A	A	A	A
Ginger Nicol	Y	Y	Y	Y
Rick Kegler	Y-S	Y	Y-S	Y-S
Kim Eisenstein	Y	Y	Y	A

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain